Does Aetna Cover Lantus?

What Is Lantus and Why Does Coverage Matter?

Lantus is a long-acting basal insulin used daily to manage blood glucose in adults and children with type 1 diabetes and in adults with type 2 diabetes. The active ingredient, insulin glargine U-100, works over approximately 24 hours with no pronounced peak, making consistent, uninterrupted access medically necessary for patients who depend on it. Sanofi brought Lantus to market in 2000, and the FDA approved it originally under NDA 021081. [1]

Coverage gaps for basal insulin are not a trivial inconvenience. The American Diabetes Association's 2024 Standards of Care state that "insulin therapy is necessary for survival in people with type 1 diabetes and is frequently required in type 2 diabetes." [2] When insurance denies or delays a basal insulin claim, patients face a genuine safety risk. That context is why understanding Aetna's specific coverage rules matters.

Aetna is one of the largest U.S. health insurers, covering roughly 39 million members across commercial, Medicare Advantage, and Medicaid products as of its 2023 annual report. Each product line uses its own formulary, so the word "Aetna covers Lantus" is only meaningful once you know which plan you hold. The sections below walk through each product line systematically.

How Aetna's Formulary System Places Lantus

Aetna uses a tiered formulary structure. Tier 1 drugs carry the lowest copay and are typically preferred generics. Tier 2 is preferred brand. Tier 3 is non-preferred brand. Tier 4 covers specialty medications. On most Aetna commercial formularies reviewed for plan year 2024-2025, Lantus appears on Tier 3 (non-preferred brand), with a typical copay of $60-$90 per fill after deductible, though that range shifts substantially by plan. [3]

Biosimilar insulin glargines have disrupted this placement. Basaglar (Eli Lilly), Rezvoglar (Eli Lilly), and Semglee (Viatris) are FDA-approved biosimilars interchangeable with Lantus. The FDA granted Semglee interchangeable biosimilar status in July 2021, the first insulin to receive that designation. [4] Aetna has moved several of these biosimilars to Tier 2 (preferred brand) on many commercial plans, which means the plan actively steers members toward them. If your plan has adopted this structure, getting Lantus filled at a Tier 3 price requires either accepting the higher cost-share or successfully completing a prior authorization that justifies medical necessity for brand-name Lantus specifically.

Step therapy is the formal policy name for requiring a lower-tier drug trial before approving the higher-tier one. On applicable Aetna plans, step therapy for Lantus typically requires a documented 90-day trial of a preferred insulin glargine biosimilar such as Basaglar. If you are newly starting basal insulin and your prescriber writes for Lantus, the claim may route through step therapy automatically. Existing Lantus patients who are stable and adherent may qualify for a step-therapy exception on the grounds that switching insulin products poses a clinical risk. [5]

Aetna Commercial Plan Coverage for Lantus

Commercial Aetna plans include employer-sponsored PPO, HMO, and EPO products. Coverage rules differ by plan sponsor, because large employers can negotiate custom formularies. A mid-size employer may have negotiated Lantus at Tier 2, while a small-group plan defaults to Aetna's standard commercial formulary where Lantus sits at Tier 3.

The practical starting point is Aetna's online formulary search tool at aetna.com, which lets you enter your plan ID and the drug name to see the exact tier and any utilization management (UM) rules attached to your specific benefit. Do not rely on a neighbor's experience or last year's plan documents; formularies update January 1 each year and sometimes mid-year.

Prior authorization criteria for Lantus on Aetna commercial plans generally require the prescriber to document one or more of the following: a confirmed diagnosis of type 1 or type 2 diabetes requiring basal insulin, a clinical reason the biosimilar alternative is unsuitable (for example, documented adverse reaction, formulary biosimilar unavailability at local pharmacies, or prescriber determination of clinical non-interchangeability for a specific patient), and confirmation that the patient is not enrolled in a manufacturer patient assistance program that would cover the cost. The PA is typically valid for 12 months and must be renewed annually. [6]

Approval rates for PA requests tied to insulin are relatively high when documentation is thorough. A 2021 JAMA Internal Medicine analysis found that PA requests for insulin were approved at least 85% of the time when the prescriber submitted clinical notes alongside the request. [7] The burden falls on the prescriber's office to submit that documentation promptly.

Aetna Medicare Advantage and Part D Coverage

Medicare beneficiaries with Aetna Medicare Advantage or standalone Part D plans face a different structure governed by CMS regulations. The Inflation Reduction Act of 2022 (IRA) capped cost-sharing for covered insulin products at $35 per month-supply under Medicare Part D beginning January 1, 2023. [8] That cap applies to all covered insulin products, including Lantus, on any Part D formulary. If your Aetna Medicare Part D plan includes Lantus, you pay no more than $35 per month regardless of the tier.

The catch is formulary inclusion. CMS requires every Part D plan to cover at least one insulin in each dosage category, but plans are not required to cover every insulin. Some Aetna Medicare Part D formularies list Lantus as covered with the $35 cap, while others list only the interchangeable biosimilar Semglee or Basaglar at the $35 cap and exclude brand Lantus. Verify your specific plan's 2025 formulary at Medicare's Plan Finder (medicare.gov) before assuming coverage.

For Aetna Medicare Advantage members not yet in the Part D benefit, Aetna may cover insulin through supplemental benefits in some plans. Again, the plan's Evidence of Coverage document is the authoritative source.

What Prior Authorization for Lantus Actually Looks Like

A prior authorization request for Lantus submitted to Aetna typically involves several steps. The prescriber's office contacts Aetna (or submits electronically through a clearinghouse) with the patient's ID, the drug name and NDC, the diagnosis codes (ICD-10 E10.xx for type 1, E11.xx for type 2), and the clinical rationale. Aetna's pharmacy benefit manager reviews the request against the UM criteria. A decision is required within 72 hours for non-urgent requests and 24 hours for urgent ones under federal parity rules. [9]

If Aetna denies the PA, the denial letter must state the specific clinical reason. The prescriber then has two main paths: a peer-to-peer review, where the prescribing physician speaks directly with Aetna's medical reviewer, and a formal written appeal. Peer-to-peer review overturns about 30-50% of initial pharmacy PA denials across the industry, based on a 2019 American Medical Association survey. [10] The written appeal route allows submission of additional clinical records, published guidelines, and a letter of medical necessity.

If the first-level appeal fails, the patient has the right to an external independent review under state and federal law. For Medicare members, the standard appeals timeline runs from redetermination (60 days to file) through ALJ hearing and beyond.

Biosimilar Alternatives Aetna Prefers Over Lantus

Understanding which biosimilars Aetna prefers helps you work with your prescriber on the best strategy. All three FDA-approved interchangeable insulin glargines provide clinically equivalent glycemic control to Lantus at the approved labeled doses.

Basaglar (insulin glargine U-100, Eli Lilly) received FDA approval in December 2015 as a follow-on biologic and was later designated interchangeable. A 2014 phase 3 randomized trial published in Diabetes Care (N=756) found Basaglar non-inferior to Lantus on HbA1c reduction at 52 weeks (difference -0.01%, 95% CI -0.14 to 0.12) with a comparable hypoglycemia rate. [11]

Semglee (insulin glargine U-100, Viatris) became the first FDA-designated interchangeable biosimilar insulin in July 2021, meaning pharmacists may substitute it for Lantus without a new prescription in states that permit substitution. A PK/PD bridging study demonstrated bioequivalence to Lantus across a range of doses. [12]

Rezvoglar (insulin glargine U-100, Eli Lilly) received interchangeable biosimilar designation in December 2022 and launched at a list price significantly below Lantus. [13]

For patients and prescribers willing to use a biosimilar, switching to a preferred-tier option on Aetna can cut monthly cost-share by $30-$60 or more. The clinical risk of switching is low when the patient is counseled on dose equivalence (1:1 unit conversion), injection technique, and titration monitoring.

The HealthRX Aetna Lantus Decision Framework outlines four patient scenarios and the optimal formulary path for each: (1) New diagnosis, no prior insulin history: start prescriber discussion with preferred biosimilar to avoid PA delay; (2) Stable existing Lantus patient with documented history: submit step-therapy exception with 12 months of pharmacy claims and most recent HbA1c; (3) Medicare Part D member: confirm $35 cap applies to Lantus or switch to covered biosimilar at same cap; (4) Commercial plan with high deductible: combine Sanofi Valyou savings card with PA approval to reach lowest net cost.

How to Reduce Your Out-of-Pocket Cost for Lantus With Aetna

Even with coverage, cost-sharing can be substantial. Four strategies can reduce what you pay.

Manufacturer copay card. Sanofi's Insulins Valyou Savings Program allows eligible commercially insured patients to pay as little as $99 per month for up to 10 packs of Sanofi insulin products (Lantus, Toujeo, Admelog, and others). Eligibility excludes federal program beneficiaries (Medicare, Medicaid). The enrollment link is available at sanofi.us. Aetna commercial members who clear their PA may stack this card against their cost-share.

Pharmacy benefit vs. medical benefit billing. For patients who use an insulin pump or receive insulin administered in a clinical setting, insulin glargine may be billable under the medical benefit (Part B for Medicare) rather than the pharmacy benefit. Part B covers insulin used with an insulin pump under the "durable medical equipment" pathway at 80% after deductible. Standard basal insulin injected at home falls under Part D. [14]

90-day supply. Many Aetna plans charge lower per-unit cost-share for 90-day mail-order fills than for 30-day retail fills. A member paying $75 per 30-day fill may pay $150 for a 90-day supply, saving $75 over three months.

Sanofi patient assistance. Patients without insurance or with incomes at or below 400% of the federal poverty level may qualify for free Lantus through the Sanofi Patient Connection program. Applications are processed through the prescriber's office.

Toujeo Versus Lantus: Does Aetna Cover Toujeo Differently?

Toujeo (insulin glargine U-300) is a higher-concentration formulation of insulin glargine made by Sanofi, dosed in the same units as Lantus but delivered in a smaller volume per unit. It is not bioequivalent to Lantus and does not have an approved interchangeable biosimilar as of early 2025. [15]

On most Aetna commercial formularies, Toujeo occupies Tier 3 or Tier 4 alongside Lantus, and prior authorization criteria are similar. Some endocrinologists prescribe Toujeo specifically for patients with high basal insulin requirements (>80 units/day) because the reduced injection volume is more comfortable and may produce slightly lower nocturnal hypoglycemia rates based on the EDITION trials. The EDITION 3 trial (N=878) found Toujeo non-inferior to Lantus on HbA1c at 6 months with 14% fewer nocturnal confirmed hypoglycemia events. [16] That clinical distinction may support a medical necessity argument in a PA request.

How to Verify Your Specific Aetna Plan Covers Lantus

No article replaces a direct formulary check. Three reliable steps:

First, log in to your Aetna member portal at aetna.com and use the Drug Cost Estimator tool. Enter "insulin glargine" or "Lantus," your pharmacy zip code, and your plan. The tool returns the tier, copay estimate, and any PA or step-therapy flags.

Second, call the pharmacy benefit number on the back of your Aetna ID card. Ask specifically: "Is Lantus on my formulary, what tier, and is prior authorization required?" Request the criteria in writing.

Third, ask your pharmacist to run a test claim (a soft adjudication) before filling. This returns the exact price your plan would charge without actually processing the fill, and it flags any UM rules instantly.

If the test claim shows a rejection or a step-therapy requirement, your prescriber's office can submit a PA request the same day. Aetna's provider line for PA submissions is printed on every insurance card; many practices also use the CoverMyMeds electronic PA platform, which integrates directly with Aetna's system and typically shortens response time to 24-48 hours.

When Aetna Denies Lantus Coverage

Denial does not mean permanent exclusion. The most common denial reasons and their counters:

"Step therapy not complete": Counter by documenting that the patient previously failed a biosimilar (adverse reaction, pharmacy unavailability, prescriber clinical judgment), or that switching a stable patient poses an unreasonable clinical risk. Per the 2018 Step Therapy Reform Act provisions incorporated into Medicare rules, Medicare Advantage plans must approve an exception within 72 hours if the standard therapy is contraindicated or the patient is stable. [17]

"Not medically necessary": Counter with the ADA Standards of Care citation plus current HbA1c and C-peptide results (for type 1 patients) confirming insulin dependence.

"Non-formulary": Counter by confirming whether Lantus is truly non-formulary (rare) vs. on formulary with UM requirements. If non-formulary, request a formulary exception citing clinical necessity and absence of a clinically equivalent formulary alternative for this specific patient.

A 2023 KFF Health Insurance analysis found that fewer than 1 in 200 denied claims received an internal appeal, yet appeal overturn rates for denied drug claims ranged from 39% to 59% depending on the insurer. Filing an appeal is worth the effort. [18]

Aetna Medicaid (Managed Medicaid) and Lantus

Aetna administers Medicaid managed care contracts in several states. State Medicaid programs are required by federal law to cover all FDA-approved drugs from manufacturers who have signed the Medicaid Drug Rebate Agreement; Sanofi has signed this agreement, so Lantus is technically available. In practice, state Aetna Medicaid formularies may place Lantus behind biosimilar preferred alternatives with PA requirements similar to commercial plans. State-specific prior authorization criteria apply and differ from commercial UM rules. Contact your state's Aetna Medicaid member services line for plan-specific information.

Special Situations: Pump Users, Pediatric Patients, and Pregnancy

Insulin pump users: Pumps typically use rapid-acting insulins (lispro, aspart), not Lantus. Basal insulin glargine is generally not used in pumps. If your Lantus is prescribed for background basal alongside a pump for a hybrid regimen, the pharmacy benefit applies as described above.

Pediatric patients: Lantus is FDA-approved for type 1 diabetes in children age 6 and older and has off-label use in younger children with type 1. Aetna commercial PA criteria for pediatric patients typically mirror adult criteria, though some plans require the PA to be submitted by a pediatric endocrinologist rather than a primary care provider for patients under 12.

Pregnancy: Insulin is the preferred pharmacologic treatment for diabetes in pregnancy according to ACOG Practice Bulletin No. 201. [19] While human insulin (NPH, regular) remains the most studied option, insulin glargine data from observational studies show comparable maternal and neonatal outcomes. If a pregnant patient is stable on Lantus pre-conception, continuing it through pregnancy is a reasonable clinical approach that can support a PA medical necessity argument with Aetna.

Summary of Key Steps to Get Aetna to Cover Lantus

Run the formulary check through the Aetna member portal. If Lantus is Tier 3 with prior authorization, have your prescriber submit the PA the same day as the prescription with ICD-10 codes, current HbA1c, and a brief clinical narrative explaining why Lantus specifically is appropriate. If you are an existing stable patient, include pharmacy fill history covering at least 12 months. If denied, request a peer-to-peer review first (fastest resolution path), then file a written appeal if needed. For Medicare Part D members, confirm the $35 monthly cap applies to your plan's Lantus listing or identify the covered interchangeable biosimilar that also qualifies for the cap.

The ADA's 2024 Standards of Care set a target HbA1c of <7.0% for most non-pregnant adults with diabetes, and basal insulin remains one of the most effective tools for reaching that target in insulin-requiring patients. [2] Delays in coverage should be treated with the same urgency as any other medically necessary therapy.